npj Vaccines (Sep 2022)
SARS-CoV-2 mRNA-vaccine candidate; COReNAPCIN®, induces robust humoral and cellular immunity in mice and non-human primates
- Reza Alimohammadi,
- Meysam Porgoo,
- Mohamad Eftekhary,
- Seyed Hossein Kiaie,
- Ehsan Ansari Dezfouli,
- Maryam Dehghani,
- Kaveh Nasrollahi,
- Talieh Malekshahabi,
- Maryam Heidari,
- Sedigheh Pouya,
- Masoumeh Alimohammadi,
- Dorsa Sattari Khavas,
- Mohammad Sadra Modaresi,
- Mohammad Hossein Ghasemi,
- Hamed Ramyar,
- Fatemeh Mohammadipour,
- Fateme Hamzelouei,
- Ahmadreza Mofayezi,
- Seyed Saeed Mottaghi,
- Amirhosein Rahmati,
- Mohsen Razzaznian,
- Vista Tirandazi,
- Mahdi Tat,
- Fatemeh Borzouee,
- Hossein Sadeghi,
- Melika Haji Mohammadi,
- Leila Rastegar,
- Seyed Milad Safar Sajadi,
- Hossein Ehsanbakhsh,
- Hamed Bazmbar,
- Zeinab Baghernejadan,
- Maedeh Shams Nouraei,
- Pouya Pazooki,
- Mina Pahlavanneshan,
- Khadijeh Alishah,
- Fateme Nasiri,
- Neda Mokhberian,
- Seyedeh Shima Mohammadi,
- Shima Akar,
- Hamidreza Niknam,
- Marzieh Azizi,
- Mohammad Ajoudanian,
- Mohammad Hossein Moteallehi-Ardakani,
- Seyed Ali Mousavi Shaegh,
- Reihaneh Ramezani,
- Vahid Salimi,
- Reza Moazzami,
- Seyed Mahmoud Hashemi,
- Somaye Dehghanizadeh,
- Vahid Khoddami
Affiliations
- Reza Alimohammadi
- Department of Immunology, ReNAP Therapeutics
- Meysam Porgoo
- Department of Process Engineering, ReNAP Therapeutics
- Mohamad Eftekhary
- Department of Quality Control, ReNAP Therapeutics
- Seyed Hossein Kiaie
- Department of Formulation Development, ReNAP Therapeutics
- Ehsan Ansari Dezfouli
- Department of Formulation Development, ReNAP Therapeutics
- Maryam Dehghani
- Department of Process Engineering, ReNAP Therapeutics
- Kaveh Nasrollahi
- Department of Genetic Engineering, ReNAP Therapeutics
- Talieh Malekshahabi
- Department of Genetic Engineering, ReNAP Therapeutics
- Maryam Heidari
- Department of Immunology, ReNAP Therapeutics
- Sedigheh Pouya
- Department of Immunology, ReNAP Therapeutics
- Masoumeh Alimohammadi
- Department of Immunology, ReNAP Therapeutics
- Dorsa Sattari Khavas
- Department of Engineering, ReNAP Therapeutics
- Mohammad Sadra Modaresi
- Department of Genetic Engineering, ReNAP Therapeutics
- Mohammad Hossein Ghasemi
- Department of Process Engineering, ReNAP Therapeutics
- Hamed Ramyar
- Department of Process Engineering, ReNAP Therapeutics
- Fatemeh Mohammadipour
- Department of Quality Control, ReNAP Therapeutics
- Fateme Hamzelouei
- Department of Quality Assurance, ReNAP Therapeutics
- Ahmadreza Mofayezi
- Department of Protein Engineering, ReNAP Therapeutics
- Seyed Saeed Mottaghi
- Department of Protein Engineering, ReNAP Therapeutics
- Amirhosein Rahmati
- Department of Protein Engineering, ReNAP Therapeutics
- Mohsen Razzaznian
- Department of Protein Engineering, ReNAP Therapeutics
- Vista Tirandazi
- Department of Quality Control, ReNAP Therapeutics
- Mahdi Tat
- Department of Genetic Engineering, ReNAP Therapeutics
- Fatemeh Borzouee
- Department of Protein Engineering, ReNAP Therapeutics
- Hossein Sadeghi
- Department of Protein Engineering, ReNAP Therapeutics
- Melika Haji Mohammadi
- Department of Chemistry, ReNAP Therapeutics
- Leila Rastegar
- Department of Chemistry, ReNAP Therapeutics
- Seyed Milad Safar Sajadi
- Department of Chemistry, ReNAP Therapeutics
- Hossein Ehsanbakhsh
- Department of Process Engineering, ReNAP Therapeutics
- Hamed Bazmbar
- Department of Process Engineering, ReNAP Therapeutics
- Zeinab Baghernejadan
- Department of Immunology, ReNAP Therapeutics
- Maedeh Shams Nouraei
- Department of Formulation Development, ReNAP Therapeutics
- Pouya Pazooki
- Department of Quality Control, ReNAP Therapeutics
- Mina Pahlavanneshan
- Department of Formulation Development, ReNAP Therapeutics
- Khadijeh Alishah
- Department of Genetic Engineering, ReNAP Therapeutics
- Fateme Nasiri
- Department of Quality Control, ReNAP Therapeutics
- Neda Mokhberian
- Department of Quality Control, ReNAP Therapeutics
- Seyedeh Shima Mohammadi
- Department of Formulation Development, ReNAP Therapeutics
- Shima Akar
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park
- Hamidreza Niknam
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park
- Marzieh Azizi
- Department of Protein Engineering, ReNAP Therapeutics
- Mohammad Ajoudanian
- Department of Engineering, ReNAP Therapeutics
- Mohammad Hossein Moteallehi-Ardakani
- Department of Protein Engineering, ReNAP Therapeutics
- Seyed Ali Mousavi Shaegh
- Rizsamaneh Behboud Darman, Mashhad Medical Technologies Science Park
- Reihaneh Ramezani
- Department of Formulation Development, ReNAP Therapeutics
- Vahid Salimi
- Department of Virology, School of Public Health, Tehran University of Medical Sciences
- Reza Moazzami
- Department of Protein Engineering, ReNAP Therapeutics
- Seyed Mahmoud Hashemi
- Department of Immunology, School of Medicine, Shahid Beheshti University of Medical Sciences
- Somaye Dehghanizadeh
- ReNAP Therapeutics
- Vahid Khoddami
- ReNAP Therapeutics
- DOI
- https://doi.org/10.1038/s41541-022-00528-3
- Journal volume & issue
-
Vol. 7,
no. 1
pp. 1 – 12
Abstract
Abstract At the forefront of biopharmaceutical industry, the messenger RNA (mRNA) technology offers a flexible and scalable platform to address the urgent need for world-wide immunization in pandemic situations. This strategic powerful platform has recently been used to immunize millions of people proving both of safety and highest level of clinical efficacy against infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here we provide preclinical report of COReNAPCIN®; a vaccine candidate against SARS-CoV-2 infection. COReNAPCIN® is a nucleoside modified mRNA-based vaccine formulated in lipid nanoparticles (LNPs) for encoding the full-length prefusion stabilized SARS-CoV-2 spike glycoprotein on the cell surface. Vaccination of C57BL/6 and BALB/c mice and rhesus macaque with COReNAPCIN® induced strong humoral responses with high titers of virus-binding and neutralizing antibodies. Upon vaccination, a robust SARS-CoV-2 specific cellular immunity was also observed in both mice and non-human primate models. Additionally, vaccination protected rhesus macaques from symptomatic SARS-CoV-2 infection and pathological damage to the lung upon challenging the animals with high viral loads of up to 2 × 108 live viral particles. Overall, our data provide supporting evidence for COReNAPCIN® as a potent vaccine candidate against SARS-CoV-2 infection for clinical studies.
